University of Vermont, Department of Psychological Science, Burlington, VT, United States.
University of Vermont, Department of Nursing, Burlington, VT, United States.
Drug Alcohol Depend. 2021 Oct 1;227:109017. doi: 10.1016/j.drugalcdep.2021.109017. Epub 2021 Sep 1.
While opioid agonists represent the most efficacious treatment for opioid use disorder (OUD), they may enhance the reinforcing effects of sweets, placing individuals at risk for weight gain and associated consequences. We examined sucrose subjective response among adults receiving opioid agonist treatment vs. a comparison sample without OUD.
Forty adults with (OUD+) and 40 without OUD (OUD-) completed an intake battery of eating behaviors and body mass index. During two same-day sessions, participants sampled six experimenter-administered sucrose solutions (0, 0.10, 0.25, 0.50, 0.75, 1.0 M), each three times, under double-blind conditions and rated the pleasantness and intensity of each.
OUD + participants presented with a higher prevalence of obesity and unhealthy eating behaviors vs. OUD- participants (p's < 0.05). They rated sucrose solutions as less pleasant than OUD- participants (p < 0.001), though this effect was limited to the three lowest concentrations (0, 0.10, 0.25M). There were no group differences on intensity ratings (p = 0.35). A change from baseline (placebo) analysis indicated a higher magnitude of change in pleasantness ratings and a lower magnitude of change in intensity ratings from 0M in OUD+ vs. OUD- (p's < 0.05).
OUD+ participants exhibited a higher magnitude of change in pleasantness ratings from placebo vs. OUD-, which was largely driven by pronounced differences in perceived pleasantness of essentially unsweet solutions. OUD+ participants presented with a consistently more severe profile in regard to eating behaviors. These data highlight the risk factors experienced by OUD+ individuals that extend beyond drug-related risks and may inform future efforts to improve health outcomes.
阿片类激动剂是治疗阿片类药物使用障碍(OUD)最有效的药物,但它们可能会增强甜食的强化作用,使个体面临体重增加和相关后果的风险。我们研究了接受阿片类激动剂治疗的成年人与没有 OUD 的对照组之间的蔗糖主观反应。
40 名患有 OUD(OUD+)的成年人和 40 名没有 OUD(OUD-)的成年人完成了饮食行为和体重指数的摄入测试。在两天的时间里,参与者在双盲条件下接受了六次实验者管理的蔗糖溶液(0、0.10、0.25、0.50、0.75、1.0M),每种溶液三次,并对每种溶液的愉悦度和强度进行了评分。
OUD+ 组参与者的肥胖和不健康饮食行为的患病率高于 OUD- 组(p 值均<0.05)。他们对蔗糖溶液的评价低于 OUD- 组(p<0.001),尽管这种效应仅限于三个最低浓度(0、0.10、0.25M)。在强度评分上没有组间差异(p=0.35)。从基线(安慰剂)分析来看,OUD+ 组在愉悦度评分上的变化幅度较大,而在强度评分上的变化幅度较小,从 0M 开始(p 值均<0.05)。
OUD+ 组在安慰剂组的愉悦度评分上的变化幅度较大,这主要是由于对基本无糖溶液的感知愉悦度有明显差异所致。OUD+ 组在饮食行为方面表现出更严重的特征。这些数据突出了 OUD+ 个体所面临的风险因素,这些风险因素不仅限于与药物相关的风险,并且可能为未来改善健康结果的努力提供信息。